The Korean Journal of Nuclear Medicine (대한핵의학회지)

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Preparation and Biodistribution of Re-188-Sulfur Colloid Suspension in Lipiodol

Re-188이 표지된 황 교질(Sulfur Colloid)/리피오돌(Lipiodol)의 제조와 생체내 분포

  • Kim, Young-Ju (Department of Nuclear Medicine, Seoul National University College of Medicine) ;
  • Jeong, Jae-Min (Department of Nuclear Medicine, Seoul National University College of Medicine) ;
  • Kim, Seok-Ki (Department of Nuclear Medicine, National Cancer Center) ;
  • Son, Mi-Won (Research Laboratories, Dong-A Pharm. Co., Ltd.) ;
  • Lee, Dong-Soo (Department of Nuclear Medicine, Seoul National University College of Medicine) ;
  • Chung, June-Key (Department of Nuclear Medicine, Seoul National University College of Medicine) ;
  • Lee, Myung-Chul (Department of Nuclear Medicine, Seoul National University College of Medicine)
  • 김영주 (서울대학교 의과대학 핵의학교실) ;
  • 정재민 (서울대학교 의과대학 핵의학교실) ;
  • 김석기 (국립 암센터 핵의학과) ;
  • 손미원 (동아제약(주) 연구소) ;
  • 이동수 (서울대학교 의과대학 핵의학교실) ;
  • 정준기 (서울대학교 의과대학 핵의학교실) ;
  • 이명철 (서울대학교 의과대학 핵의학교실)
  • Published : 2003.10.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Lipiodol is used for targeting liver cancers by administrating through the hepatic artery. In the present study, feasibility of Re-188-sulfur colloid suspension in lipiodol as a liver cancer targeting agent was investigated. Materials and Methods: Re-188-sulfur colloid was prepared, harvested by centrifugation, washed with organic solvent and then suspended into lipiodol. Biodistribution of Re-188-sulfur colloid in normal saline and its suspension in lipiodol in mice after 1 hr of injection through the tail vein were investigated. Biodistribution and autoradiography of tumor-hearing liver was acquired after 5 min post-injection into left ventricle of the tumor-inoculated rats. Results: After 1 hr of injection with Re-188-sulfur colloid suspensiob in lipiodol through the tail vein in normal mice (n=3), the uptakes in the liver and lung were $5.2{\pm}0.7\;and\;91.0{\pm}1.7%$ ID/organ, respectively. After 5 min of injection with Re-188-sulfur colloid suspention in lipiodol through the left ventricle in the tumor-inoculated rats (n=4), uptakes in the normal liver, hepatoma, and lung were $0.41{\pm}0.28,\;1.88{\pm}1.57,\;and\;1.65{\pm}1.54%$ ID/organ, respectively. And autoradiography of hepatoma showed increased uptake than normal liver tissues. Conclusion: Re-188-sulfur colloid suspension in lipiodol injected through the artery shows higher uptake in the hepatoma than normal liver tissue that indicates the feasibility as a new radiopharmaceutical for therapy of hepatoma.

목적: 리피오돌은 간암환자의 간동맥으로 투여시 암에 많이 섭취된다. 이 연구에서는 Re-188-황 교질/리피오돌을 제조하여 생체내분포를 보았다. 재료 및 방법: Re-188-황 교질/리피오돌을 마우스의 꼬리정맥으로 주사한후 1 시간 후에 생체내 분포를 확인하였다. 간암을 유발시킨 백서의 좌심실로 Re-188-황 교질/리피오돌을 주사하고 5 분후의 생체내 분포와 간의 자가방사사진을 보았다. 결과: Re-188-황 교질/리피오돌을 마우스의 꼬리정맥으로 주사한 후 1시간(n=3)섭취율(% ID/organ)은 간에서 $5.2{\pm}0.7$, 폐는 $91.0{\pm}1.7$이었다. 간암을 유발시킨 백서의 좌심실로 Re-188-황 교질/리피오돌을 주사한 후 5 분(n=4)의 정상간의 섭취율(% ID/g)은 $0.41{\pm}0.28$, 간암은 $1.88{\pm}1.57$, 폐는 $1.65{\pm}1.54$였으며, 자가방사사진에서도 간암부위의 섭취가 정상적인 간조직 보다 증가되었다. 결론: Re-188-황 교질/리피오돌을 동맥으로 투여시 간암부위의 섭취가 정상적인 간조직보다 많아 간암치료용 방사성의약품으로서 사용할 수 있음을 알았다.

Keywords

References

  1. Jeong JM, Kim YJ, Lee YS, Ko JI,, Son M, Lee DS, et al. Lipiodol solution of a lipiodol agent, $^188$Re-TDD, for the treatment of liver cancer. Nucl Med Biol 2001;28: 197-204 https://doi.org/10.1016/S0969-8051(00)00208-0
  2. Wang S-J, Lin W-Y, Chen M-N, Hsieh B-T, Shen L-H, Tsai Z-T, et al. Biodistribution of rhenium-188 lipiodol infused via the hepatic artery of rats with hepatic tumours. Eur J Nucl Med 1996;23: 13-7 https://doi.org/10.1007/BF01736984
  3. Lencieoni R, Vignali C, Caramella D, Cioni R, Mazzeo S, Bartolozzi C. Transcatheter arterial embolization followed by percutaneous ethanol injection in the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 1994;17:70-5
  4. Trinchet J-C, Rached AA, Beaugrand M, Mathieu D, Cheveret S, Chastang C. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. New Engl J Med 1995;332: 1256-61 https://doi.org/10.1056/NEJM199505113321903
  5. Nakamura H, Hashimoto T, Oi H, Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989;170: 783-6
  6. Madsen MT, Park CH, Takur ML. Dosimetry of iodine-131 ethiodol in the treatment of hepatoma, J Nucl Med 1988;29: 1038-44
  7. Nakajo M, Kobayashi H, Shimabukuro K, Shirono K, Sakata H, Taguchi M, et al. Biodistribution and in vivo kinetics of iodine-131 lipiodol infused via the hepatic artery of patients with hepatic cancer. J Nucl Med 1988;29: 1066-77
  8. Park CH, Suh JH, Yoo HS. Evaluation of intrahepatic I-131 ethiodol on a patient with hepatocellular carcinoma. Clin Nucl Med 1986;11:514-7 https://doi.org/10.1097/00003072-198607000-00015
  9. Park CH, Yoo HS, Lee JT, Kim DI. Iodine-131-labeled lipiodol retention within hepatic cavernous hemangioma. Radiology 1987;163: 283-4 https://doi.org/10.1148/radiology.163.1.3029805
  10. Yoo HS, Suh JH, Lee JT, Kim DI, Park CY, Kim BS, et al. Therapeutic feasibility study and clinical trial of intrahepatic I-131-lipiodol on patients with hepatocellular carcinoma. Korean J Nucl Med 1986;20: 61-71
  11. Chen MN, Wang SJ, Kao CH, Tsai ZT. A column method for lipiodol labeling with yttrium-90 [abstract]. J Nucl Med 1994;35: 241p
  12. Wang S-J, Lin W-Y, Chen M-N, Shen L-H, Tsai Z-T, Ting G. Preparation and biodistribution of yttrium-90 lipiodol in rats following hepartic arterial injection. Eur J Nucl Med 1995;22: 233-6 https://doi.org/10.1007/BF01081518
  13. Wang S-J, Lin W-Y, Chen M-N, Hsieh B-T, Shen L-H, Tsai Z-T, et al. Radiolabeling of lipiodol with generator-produced 188Re for hepartic tumor therapy. Appl Radiat Isot 1996;47: 267-71 https://doi.org/10.1016/0969-8043(95)00300-2
  14. Kim YJ, Jeong JM, Chang YS, Lee YJ, Lee DS Chung J-K, et al. Preparation and biodistribution of Re-188 sulfur colloid, Koraen J Nucl Med 1998;32:298-304
  15. Venkatesan PP, Shorkroff S, Zalutsky MR, Sledge CB. Rhenium heptasulfide: a potential carrier system for radiation synovectomy. Nucl Med Biol 1990;17: 357-62
  16. Wang S-J, Lin W-Y, Hsieh B-T, Shen L-H, Tsai Z-T, Ting G, et al. Rhenium-188 sulphur colloid as a radiation synovectomy agent. Eur J Nucl Med 1995;22: 505-7 https://doi.org/10.1007/BF00817272
  17. Yu J, Hafeli UO, Sands M, Dong Y. 90Y-oxine-ethiodol, a potential radiopharmaceutical for the treatment of liver cancer. Appl Radiat Isot 2003;58: 567-73 https://doi.org/10.1016/S0969-8043(03)00064-2
  18. Lee Y-S, Jeong JM, Kim YJ, Chung JW, Park JH, Suh Y-G, et al. Sythesis of 188Re-labelled long chain alkyl diaminedithiol for therapy of liver cancer. Nucl Med Commun 2002;23: 237-42 https://doi.org/10.1097/00006231-200203000-00006